CTIS2023-504597-37-00
Recruiting
Phase 1
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) - DMX-200-301
Dimerix Bioscience Pty Limited0 sites326 target enrollmentMay 3, 2023
ConditionsFocal segmental glomerulosclerosisMedDRA version: 21.1Level: LLTClassification code: 10016832Term: Focal & segmental glomerulosclerosis Class: 10038359MedDRA version: 21.1Level: PTClassification code: 10067757Term: Focal segmental glomerulosclerosis Class: 100000004857Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Focal segmental glomerulosclerosis
- Sponsor
- Dimerix Bioscience Pty Limited
- Enrollment
- 326
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Primary FSGS, genetic FSGS, or FSGS of undetermined cause (FSGS\-UC). NOTE: Primary FSGS and FSGS\-UC must be biopsy\-proven. The kidney biopsy could have been obtained at any time and should be based on light microscopy with supportive findings on either electron microscopy or immunofluorescence. No biopsy is required where there is a documented genetic mutation of a podocyte protein associated with FSGS. All patients should demonstrate a clinical history and disease course consistent with FSGS, OLE: The patient received blinded IP throughout the duration of the double\-blind period up to the Week 104 (EOT – DB) visit (ie, did not permanently discontinue the IP)., Must be either receiving an ARB at the maximal tolerated dose and \= 50% of the maximum recommended dose per the product label prior to Screening, or willing to transition to this treatment, If taking corticosteroids, the dosage must be stable for \=4 weeks prior to Screening and during Stabilization, and patients must have no plan to change their treatment regimen during study, If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, sodium\-glucose co\-transporter\-2 inhibitors, or endothelin receptor antagonists (including dual antagonists), the dose and regimen must be stable for \=12 weeks prior to Screening and during Stabilization and patients must have no plan to change their treatment regimen during the study, Urine protein/creatinine ratio (PCR) \>1\.5 g/g (\>169\.5 mg/mmol) or 24\-hour total protein \>1\.5 g/day based on 24\-hour urine collection during Screening, Estimated glomerular filtration rate (eGFR) \=25 mL/min/1\.73 m2 at Screening using the CKD Epidemiology Collaboration (CKD\-EPI) Creatinine Equation (2009\) for patients \=18 years of age or the Modified Schwartz formula for patients \<18 years of age, Seated blood pressure \=160/100 mm Hg (mean of 3 values) (patients \=18 years of age) or between the 5th and 95th percentile for age, sex, and height (patients \<18 years of age) at Screening, Body weight \=35 kg (all patients) AND a body mass index (BMI) \=40 kg/m2 (patients \=18 years of age) or between the 5th and 98th percentile for age and sex (patients \<18 years of age) at Screening. For patients with moderate or severe edema, BMI will be calculated based on remission or premorbid weight measured within 3 months prior to Screening, if available. If not available, BMI will be calculated based on the estimated dry weight, based on the Investigator’s clinical judgment, OLE: Patients who have completed participation in the double\-blind period, including the Week 104 visit, and who may derive benefit from (continued) treatment with DMX\-200, and/or continued follow\-up, as assessed by the Investigator, in consultation and agreement with the Medical Monitor.
Exclusion Criteria
- •Has FSGS secondary to another condition, OLE: Any safety concerns identified during the double\-blind period which, in the Investigator’s opinion, may interfere with the patient’s continued participation during the OLE period., History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as glycated hemoglobin \>8%), History of lymphoma, leukemia, or any active malignancy within the past 2 years (except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ that have been resected and with no evidence of metastatic disease), Active clinically significant hepatobiliary disease, Documented history of heart failure (New York Heart Association Class III/IV) or a major adverse cardiac event within 12 weeks prior to Screening, Serum potassium levels \>5\.5 mmol/L at Screening, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \>2 × upper limit of normal at Screening, Treatment with immunosuppressant biological drugs, calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 12 weeks prior to Screening, OLE: The patient has met the criteria for permanent IP discontinuation as defined in Section 7\.1 or study discontinuation as defined in Section 7\.2 at Week 104, or prior to the first open\-label dose of DMX 200 at Week 108\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisFocal segmental glomerulosclerosisMedDRA version: 21.1Level: PTClassification code 10067757Term: Focal segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 21.1Level: LLTClassification code 10016832Term: Focal & segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2021-004174-64-ESDimerix Bioscience Pty Ltd286
Recruiting
Phase 3
A Pivotal Phase 3 Study of the Efficacy and Safety of DMX-200 in Patients With focal segmental glomerulosclerosis (FSGS) Who Are Receiving an angiotensin II receptor blocker (ARB)Focal segmental glomerulosclerosis (FSGS)Renal and Urogenital - Kidney diseaseACTRN12622000066785Dimerix Bioscience Pty Ltd286
Active, not recruiting
Phase 1
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisEUCTR2021-004174-64-DKDimerix Bioscience Pty Ltd286
Active, not recruiting
Phase 3
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisFocal segmental glomerulosclerosisUrological and Genital DiseasesISRCTN72772236Dimerix Bioscience Pty Ltd286
Active, not recruiting
Phase 1
A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 given as a single dose (4.8g/day) in subject with acute mild to moderate ulcerative colitis.Subjects who have newly diagnosed or have a diagnosis of relapsing (relapses<to baseline) mild to moderate ulcerative colitis (UC). The original diagnosis of UC (total score of 4-10 on the Ulcerative Colitis Disease Activity Index and with a sigmoidoscopy score of >1 and a Physician Global Assessment of <2). The original diagnosis of UC must be established by sigmoidoscopy, colonoscopy, or barium enema and have compatible histology.EUCTR2004-000733-12-CZShire Pharmaceutical Development Inc255